NewsEuropeGerman Medical Cannabis Scripts Mainly For Pain

German Medical Cannabis Scripts Mainly For Pain

-

PAIN is most common ailment for which patients are prescribed medical cannabis, say the German Government 

The introduction of its medical cannabis programme in 2017 saw physicians allowed to prescribe medicinal cannabis for over 60 illnesses.

Almost three quarters of all prescriptions from a Government sample of over 6,500 are for pain – at 71%

This was followed by spasticity – a muscle condition at 11% – and anorexia at 7%, with epilepsy,  migraines, ADHD and Tourettes Syndrome all featuring, too.

The data is based on an ongoing government survey involving 6,538 patients, as of September last year, reports the Marijuana Business Daily website.

This survey on the medical market will run until March 2022 and will then be used determine the future of medical cannabis insurance coverage.

Germany’s medical cannabis programme began in March 2017, and 

‘The Germany Cannabis Report’  by  Prohibition Partners  estimates 60,000 patients have been helped.

One of the most pressing issues in the German market is that it does not have the supply chain to satiate demand and has consequently granted supply licenses to three Canadian, and one domestic, producer while it  encourages the development of a homegrown industry.

This comes an estimated four million Germans use cannabis, with 17% of 18 to 25-year-olds saying they had used it in the past 12 months.

Despite being illegal, the state will not usually prosecute anyone found to have six grams of cannabis, or less – a limit agreed by state interior ministers, in 2018.

https://mjbizdaily.com/new-data-reveals-to



Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Thought Leaders Acquisition Of mellow Set To Accelerate Growth Across UK, Europe, And Asia Footprint

THE CBD world is set with a massive shake-up this week as Thought Leaders, the US cannabis & CBD investment company,...

Medical Cannabis Cost-Benefit Analysis Set To Be Launched By UK CIC At A Cost of £30,000

THE initial priorities of the UK Cannabis Industry Council have been identified following a special general meeting attended by...

CIC Research Group Looking To Overcome The ‘Scandalous’ Impasse On UK Medical Cannabis Prescribing

Chartered Psychologist and Head of Research at Drug Science, Dr Anne Katrin Schlag, heads up the newly formed Cannabis...

European Cannabis Market Leader Bloomwell Group Secures $10m Investment

The Bloomwell Group has successfully closed a seed funding round of over $10 million dollars—the highest publicly known seed investment...

German Hemp Farm Numbers Up 900% In Seven Years – As industry Calls For Post-Election Reform

THE number of German farms growing industrial hemp has hit 863 – the highest figure since the federal republic...

US Company Set To Launch UK Medical Cannabis Study In Partnership With Manchester University

A GROUND-BREAKING human pilot study centred on the University of Manchester could provide answers to using cannabis as a...

Must read

Medical Cannabis Cost-Benefit Analysis Set To Be Launched By UK CIC At A Cost of £30,000

THE initial priorities of the UK Cannabis Industry Council...

CIC Research Group Looking To Overcome The ‘Scandalous’ Impasse On UK Medical Cannabis Prescribing

Chartered Psychologist and Head of Research at Drug Science,...

You might also likeRELATED
Recommended to you